Phathom Q3 revenue up 25%, beats estimates

Phathom Pharmaceuticals

30/10/2025 11:19

Overview

Phathom Q3 2025 revenue rises 25% quarter-over-quarter, beating analyst expectations

Company updates 2025 revenue guidance to $170–$175 mln, expects profitability in 2026

Cash operating expenses down 43% quarter-over-quarter, aligning with cost-saving plans

Outlook

Phathom updates 2025 revenue guidance to $170–$175 mln

Company expects operating profitability in 2026

Phathom anticipates VOQUEZNA exclusivity through May 2032

Result Drivers

VOQUEZNA PRESCRIPTIONS - 28% increase in filled VOQUEZNA prescriptions drove revenue growth, supported by strategic sales force retargeting efforts

COST SAVINGS - Significant reduction in operating expenses due to lower promotional spend and personnel costs

COMMERCIAL COVERAGE - Stable commercial coverage with over 80% of U.S. lives covered supports revenue growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$49.50 mln
$46.99 mln (8 Analysts)
Q3 Net Income
-$30 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Phathom Pharmaceuticals Inc is $20.00, about 32.4% above its October 29 closing price of $13.53

Press Release: ID:nGNXbdJTKV

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)